摘要
肿瘤化疗相关贫血(chemotherapy-related anemia,CRA)为肿瘤患者常见的不良反应,发生率与肿瘤类型、治疗方案和化疗周期等均有关,其发病机制尚未明确。CRA可能导致化疗药物剂量减少、化疗时间延迟、需要输注红细胞等,从而增加患者的治疗费用、降低化疗效果和患者的生存质量、缩短生存时间。CRA的主要治疗包括输注红细胞、促红细胞生成治疗和补充铁剂等。基于近期文献和临床研究,中国抗癌协会肿瘤临床化疗专业委员会和肿瘤支持治疗专业委员会制定了《中国肿瘤化疗相关贫血诊治专家共识(2019年版)》,旨在为中国肿瘤学医师提供更为合理的诊疗方案,从而帮助患者改善CRA,提高生存质量。
Cancer and chemotherapy-related anemia(CRA)is a common side effect in patients with tumors,the incidence of which is related to tumor type,treatment regimen,the duration of chemotherapy,etc.The pathogenesis of CRA has not been fully defined.CRA may lead to chemotherapy dose reduction or may even delay chemotherapy.Patients with CRA require red blood cell transfusion,thus increasing the treatment cost,reducing the efficiency of chemotherapy and the patient's quality of life,and shortening the survival time.The main treatments of CRA include red blood cell transfusion,iron supplements,erythropoietin,and so on.Based on recent literature and clinical studies,the Society of Chemotherapy,Chinese Anti-Cancer Association and Committee of Neoplastic Supportive-care(CONS),China Anti-Cancer Association drew up the consensus on the clinical diagnosis,treatment,and prevention of cancer and chemotherapy-related anemia in China(2019 edition),aiming to provide more reliable diagnosis and treatment plans for Chinese oncologists to help improve CRA and the quality of life in patients with tumors.
作者
无
史艳侠
邢镨元
张俊
沈波
姜文奇
巴一
冯继锋
无;BA Yi(The Society of Chemotherapy,Chinese Anti-Cancer Association;Committee of Neoplastic Supportive-care(CONS),China Anti-Cancer Association;不详)
出处
《中国医学前沿杂志（电子版）》
2019年第12期78-85,共8页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
肿瘤
化疗
贫血
铁剂
促红细胞生成治疗
Tumor
Chemotherapy
Anemia
Iron supplements
Erythropoiesis therapy
